FDA Inspection 1169916 — Oklahoma Blood Institute
The FDA completed an inspection of Oklahoma Blood Institute on Apr 28, 2022 in Little Rock, AR. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 28, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Little Rock, AR (United States)